Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays

American Journal of Clinical Pathology

Volumn 126, Issue 1, 2006, Pages 101-109

  Mayr, Doris ^a   Kanitz, Veronika ^a   Anderegg, Birgit ^b   Luthardt, Beate ^a   Engel, Jutta ^c   Löhrs, Udo ^a   Amann, Gudrun ^d   Diebold, Joachim ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

^c Munich Tumour Registry   (Germany)

^d Sloning BioTechnology   (Germany)

Author keywords

CGH array; Comparative genomic hybridization; Cyclin E; Immunohistochemistry; Oncogenes; Ovarian tumors; Tissue microarray

Indexed keywords

FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GENE PRODUCT; P21 ACTIVATED KINASE 1; PROTEIN CCND2; PROTEIN CCNE1; PROTEIN ESR; PROTEIN KRAS2; PROTEIN MDM2; PROTEIN MYCN; PROTEIN PIK3CA; TRANSCRIPTION FACTOR JUNB; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA MICROARRAY; ENDOMETRIUM CARCINOMA; FEMALE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENOMICS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; ONCOGENE; OVARY CANCER; OVARY CARCINOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

CYSTADENOCARCINOMA, SEROUS; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745776277     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/N6X5MB24BP42KP20     Document Type: Article

References (33)

1. Kallioniemi A, Kallioniemi O-P, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992;258:818-821.
2. Kallioniemi A, Visakorpi T, Karhu R, et al. Gene copy number analysis by fluorescence in situ hybridization and comparative genomic hybridization. Methods. 1996;9:113-121.
3. Speicher MR, du Manoir S, Schröck E, et al. Molecular cytogenetic analysis of formalin-fixed, paraffin-embedded solid tumors by comparative genomic hybridization after universal DNA-amplification. Hum Mol Genet. 1993;2:1907-1914.
4. du Manoir S, Schröck E, Bentz M, et al. Quantitative analysis of comparative genomic hybridization. Cytometry. 1995;19:27-41.
5. Daigo Y, Chin S-F, Gorringe KL, et al. Degenerate oligonucleotide primed-polymerase chain reaction-based array comparative genomic hybridization for extensive amplicon profiling of breast cancers: a new approach for the molecular analysis of paraffin-embedded cancer tissue. Am J Pathol. 2001;158:1623-1631.
6. Callagy G, Pharoah P, Chin S-F, et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol. 2005;205:388-396.
7. Isola J, DeVries S, Chu L, et al. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol. 1994;145:1301-1308.
8. Mayr D, Kaltz-Wittmer C, Arbogast S, et al. Characteristic pattern of genetic aberrations in ovarian granulosa cell tumors. Mod Pathol. 2002;15:951-957.
9. Henegariu O, Heerema NA, Wright LL, et al. Improvements in cytogenetic slide preparation: controlled chromosome spreading, chemical aging and gradual denaturing. Cytometry. 2001;43:101-109.
10. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72.
11. Simon R, Richter J, Wagner U, et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 2001;61:4514-4519.
12. Schraml P, Schwerdtfeger G, Burkhalter F, et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-a14 as a critical oncogene target in ovarian carcinoma. Am J Pathol, 2003;163:985-992.
13. Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell. 2004;119:431-443.
14. Mao X, Orchard G, Lillington DM, et al. BCL2 and JUNB abnormalities in primary cutaneous lymphomas. Br J Dermatol. 2004;151:546-556.
15. Tanimura S, Ohtsuka S, Mitsui K, et al. MDM2 interacts with MDMX through their ring finger domains. FEBS Lett. 1999;447:5-9.
16. Palazzo JP, Monzon F, Burke M, et al. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumours. Hum Pathol. 2000;31:698-704.
17. Campbell IG, Russell SE, Choong DYH, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678-7681.
18. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3:1221-1224.
19. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A. 2005;102:801-807.
20. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004;18:2699-2711.
21. Tsuda H, Bandera CA, Birrer MJ, et al. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology. 2004;67:291-299.
22. Schraml P, Bucher C, Bissig H, et al. Cyclin E overexpression and amplification in human tumours. J Pathol. 2003;200:375-382.
23. Mussman JG, Horn HF, Carroll PE, et al. Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression. Oncogene. 2000;19:1635-1646.
24. Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther. 2003;2:38-47.
25. Akli S, Zheng P-J, Multani AS, et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res. 2004;64:3198-3208.
26. Harwell RM, Porter DC, Danes C, et al. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res. 2000;60:481-489.
27. 1 cyclins in cell proliferation and prognosis. Cancer Res. 2001;61:2500-2504.
28. kip1, cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol. 2001;83:56-63.
29. Yamanouchi H, Furihata M, Fujita J, et al. Expression of cyclin E and cyclin D1 in non-small cell lung cancers. Lung Cancer. 2001;31:3-8.
30. KIP2, cyclin D1, and cyclin E in epithelial ovarian tumours and survival. Hum Pathol. 2001;32:808-813.
31. Farley J, Smith LM, Darcy KM, et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res. 2003;63:1235-1241.
32. Sawasaki T, Shigemasa K, Shiroyama Y, et al. Cyclin E mRNA overexpression in epithelial ovarian cancers: inverse correlation with p53 protein accumulation. J Soc Gynecol Investig. 2001;8:179-185.
33. Session DR, Lee GS, Choi J, et al. Expression of cyclin E in gynaecologic malignancies. Gynecol Oncol. 1999;72:32-37.